Celgene (acquired by Bristol Myers Squibb)

Celgene was a biopharmaceutical company known for developing innovative drugs, particularly in cancer and immunology. Its most notable product, Revlimid, treats multiple myeloma and other conditions. In 2019, Celgene was acquired by Bristol Myers Squibb, a larger pharmaceutical company, for approximately $74 billion. This acquisition aimed to enhance Bristol Myers Squibb's portfolio and strengthen its position in the oncology market, allowing for greater investment in research and development of new therapies to improve patient outcomes in various diseases.